豪尔赛科技集团股份有限公司 章程 豪尔赛科技集团股份有限公司 章 程 豪尔赛科技集团股份有限公 司 章程 目 录 豪尔赛科技集团股份有限公司 章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行 为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 豪尔赛科技集团股份有限公司（以下简称"公司"）系依照《公司法》 和其他有关规定成立的股份有限公司，公司由豪尔赛照明技术集团有限公司整体 变更发起设立，在北京市市场监督管理局注册登记，领取营业执照，统一社会信 用代码 91110108723950093X。 第三条 公司于 2019 年 9 月 12 日经中国证券监督管理委员会（简称"中国 证监会"）核准，首次向社会公众公开发行人民币普通股 3,759 万股，于 2019 年 第四条 公司注册名称：豪尔赛科技集团股份有限公司。 英文名称：Haoersai Technology Group Corp., Ltd. 第五条 公司住所：北京市海淀区中关村南大街 17 号 3 号楼 1903 室，邮政 ...

Financial Data and Key Metrics Changes - LabCorp reported exceptional results in 2024, with strong momentum heading into 2025, indicating a positive outlook for financial performance [4] - At least 91% of shares voted in favor of the nonbinding advisory approval of the company's compensation for named executive officers, reflecting shareholder confidence [30] - The approval rate for the company's 2025 omnibus incentive plan was at least 94%, and for the employee stock purchase plan, it was at least 99% [30] Business Line Data and Key Metrics Changes - The diagnostics and biopharma laboratory services businesses made meaningful advances through organic growth and transformative acquisitions, contributing to the overall success of LabCorp [4] Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the meeting [0] Company Strategy and Development Direction - LabCorp is focused on improving health and lives while generating attractive returns for shareholders, positioning itself well for future growth [4] - The company emphasizes ethical and regulatory responsibilities in its biopharma laboratory services, particularly regarding animal welfare and research integrity [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LabCorp's positioning for continued success in 2025, highlighting the importance of their strategic initiatives [4] - The company is committed to high standards of animal care and welfare, which is fundamental to sound scientific research [35] Other Important Information - The meeting included the election of directors, approval of executive compensation, and ratification of the independent registered public accounting firm for 2025, all of which passed with significant support from shareholders [30] Q&A Session Summary Question: What specific measures is LabCorp taking to mitigate biosafety and public health risks associated with research animals? - LabCorp takes its ethical and regulatory responsibilities seriously, ensuring the health and wellness of research animals, which is fundamental to scientific research [35] - The company has a dedicated global team to establish high standards of animal care and welfare, proactively identifying and mitigating risks [36]

Core Viewpoint - AnDuoMai A (000553) has shown a mixed performance in its recent financial results, with a decline in revenue but a significant increase in net profit, indicating potential areas for investment consideration. Trading Information Summary - On April 29, 2025, AnDuoMai A closed at 6.09 yuan, up 6.47%, with a turnover rate of 0.79%, a trading volume of 171,600 shares, and a transaction value of 104 million yuan [1] - The fund flow on the same day showed a net outflow of 4.35 million yuan from main funds, while retail investors contributed a net inflow of 1.40 million yuan [2][7] Shareholder Changes - As of March 31, 2025, the number of shareholders for AnDuoMai A decreased to 29,500, a reduction of 1,832 shareholders or 5.85% since January 27 [3][7] - The average number of shares held per shareholder increased from 72,200 to 73,800, with an average market value of 433,500 yuan per shareholder [3] Performance Disclosure Highlights - In the first quarter of 2025, AnDuoMai A reported a main revenue of 7.173 billion yuan, a year-on-year decrease of 4.48% [4][7] - The net profit attributable to shareholders reached 151 million yuan, a significant increase of 166.4% year-on-year, while the net profit excluding non-recurring items was 102 million yuan, up 140.5% year-on-year [4][7] - The company's debt ratio stood at 62.51%, with investment income of 4.671 million yuan and financial expenses of 22.151 million yuan, alongside a gross profit margin of 27.17% [4]

公司章程 浙江核新同花顺网络信息股份有限公司 章程 1 公司章程 目 录 第一节 通知 2 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东 第二节 股东会的一般规定 第三节 股东会的召集 第四节 股东会的提案与通知 第五节 股东会的召开 第六节 股东会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知和公告 公司章程 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 3 第二节 解散和清算 第十一章 修改章程 第十二章 附则 公司章程 浙江核新同花顺网络信息股份有限公司章程 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 （以下简称《证券法》）和其他有关规定， ...